› Forums › General Melanoma Community › Merck-Rolling Submission-License Application for MK-3475
- This topic has 9 replies, 3 voices, and was last updated 11 years, 4 months ago by
Golda_.
- Post
-
- January 13, 2014 at 3:56 pm
Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma
Expects to Complete Application in First Half of 2014January 13, 2014 08:30 AM Eastern Standard TimeRead more: Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma – FierceBiotech http://www.fiercebiotech.com/press-releases/merck-initiates-rolling-submission-us-biologics-license-application-mk-3475#ixzz2qIJiIsJ6
Subscribe at FierceBiotech
- Replies
-
-
- January 13, 2014 at 5:25 pm
Jerry, thanks for posting. The market certainly likes the news: "Shares of Merck & Co rose as much as 6 percent on Monday after the company filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma."
Although not crystal clear, the wording of the article you posted suggests that the initial approval may be for those who have tried ipi first.
To me, this also puts pressure on BMS to get nivo approved in 2014.
-
- January 13, 2014 at 5:25 pm
Jerry, thanks for posting. The market certainly likes the news: "Shares of Merck & Co rose as much as 6 percent on Monday after the company filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma."
Although not crystal clear, the wording of the article you posted suggests that the initial approval may be for those who have tried ipi first.
To me, this also puts pressure on BMS to get nivo approved in 2014.
-
- January 13, 2014 at 5:25 pm
Jerry, thanks for posting. The market certainly likes the news: "Shares of Merck & Co rose as much as 6 percent on Monday after the company filed the first part of an application to market its experimental drug, MK-3475, for advanced melanoma."
Although not crystal clear, the wording of the article you posted suggests that the initial approval may be for those who have tried ipi first.
To me, this also puts pressure on BMS to get nivo approved in 2014.
-
- You must be logged in to reply to this topic.